# Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma

> **NCT05738161** · PHASE1 · WITHDRAWN · sponsor: **Insel Gruppe AG, University Hospital Bern**

## Conditions studied

- Advanced Urothelial Carcinoma

## Interventions

- **DRUG:** Magrolimab
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT05738161
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-06-21
- **Primary completion:** 2024-02-27
- **Final completion:** 2024-02-27
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** IMP security Issues reported by Sponsor
- **Last updated:** 2024-07-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05738161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05738161, "Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05738161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*